 WIXOM, Mich., June 28, 2021 GLOBE NEWSWIRE -- Rockwell Medical, Inc. Nasdaq: RMTI, a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has submitted a pre-IND Investigational New Drug meeting request with the U.S. Food and Drug Administration FDA in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate FPC, designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting. 